Cargando…

靶向治疗背景下非小细胞肺癌传统化疗的地位与发展

In recent years, along with rapid development of targeted therapy in non-small cell lung cancer, traditional chemotherapy get less and less attention. Yet it still can not be ignored in the current that how to locate and use traditional chemotherapy so patients could derive maximum benefit. For this...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000116/
https://www.ncbi.nlm.nih.gov/pubmed/26383984
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.10
_version_ 1783331624049442816
collection PubMed
description In recent years, along with rapid development of targeted therapy in non-small cell lung cancer, traditional chemotherapy get less and less attention. Yet it still can not be ignored in the current that how to locate and use traditional chemotherapy so patients could derive maximum benefit. For this purpose, through the literature review and analysis, we point out there are still many traditional chemotherapy irreplaceable places whatever patients' driver gene status. And there are some new treatment modalities of traditional chemotherapy which have been developed to further improve patients' survival. At the same time, through exposition of predictive bio-markers development in chemotherapy, we pointed out that the future of traditional chemotherapy must be part of "targeted therapy".
format Online
Article
Text
id pubmed-6000116
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60001162018-07-06 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展 Zhongguo Fei Ai Za Zhi 综述 In recent years, along with rapid development of targeted therapy in non-small cell lung cancer, traditional chemotherapy get less and less attention. Yet it still can not be ignored in the current that how to locate and use traditional chemotherapy so patients could derive maximum benefit. For this purpose, through the literature review and analysis, we point out there are still many traditional chemotherapy irreplaceable places whatever patients' driver gene status. And there are some new treatment modalities of traditional chemotherapy which have been developed to further improve patients' survival. At the same time, through exposition of predictive bio-markers development in chemotherapy, we pointed out that the future of traditional chemotherapy must be part of "targeted therapy". 中国肺癌杂志编辑部 2015-09-20 /pmc/articles/PMC6000116/ /pubmed/26383984 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.10 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
title 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
title_full 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
title_fullStr 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
title_full_unstemmed 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
title_short 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
title_sort 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000116/
https://www.ncbi.nlm.nih.gov/pubmed/26383984
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.10
work_keys_str_mv AT bǎxiàngzhìliáobèijǐngxiàfēixiǎoxìbāofèiáichuántǒnghuàliáodedewèiyǔfāzhǎn
AT bǎxiàngzhìliáobèijǐngxiàfēixiǎoxìbāofèiáichuántǒnghuàliáodedewèiyǔfāzhǎn
AT bǎxiàngzhìliáobèijǐngxiàfēixiǎoxìbāofèiáichuántǒnghuàliáodedewèiyǔfāzhǎn
AT bǎxiàngzhìliáobèijǐngxiàfēixiǎoxìbāofèiáichuántǒnghuàliáodedewèiyǔfāzhǎn
AT bǎxiàngzhìliáobèijǐngxiàfēixiǎoxìbāofèiáichuántǒnghuàliáodedewèiyǔfāzhǎn